Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 7.77
(1.17%)
SEK 7.77
(1.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 40.85 Million SEK | -16.48% |
| 2022 | 48.92 Million SEK | -27.9% |
| 2021 | 67.85 Million SEK | 30.48% |
| 2020 | 52 Million SEK | 166.53% |
| 2019 | 19.51 Million SEK | 20.71% |
| 2018 | 16.16 Million SEK | 146.44% |
| 2017 | 6.55 Million SEK | 8.36% |
| 2016 | 6.05 Million SEK | -17.03% |
| 2015 | 7.29 Million SEK | 28.61% |
| 2014 | 5.67 Million SEK | -48.3% |
| 2013 | 10.97 Million SEK | 90651.92% |
| 2012 | 12.08 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 51.82 Million SEK | 26.85% |
| 2024 Q2 | 43.75 Million SEK | -15.59% |
| 2023 FY | 40.85 Million SEK | -16.48% |
| 2023 Q4 | 40.85 Million SEK | -11.3% |
| 2023 Q1 | 39.94 Million SEK | -18.35% |
| 2023 Q2 | 37.96 Million SEK | -4.96% |
| 2023 Q3 | 46.06 Million SEK | 21.34% |
| 2022 Q4 | 48.92 Million SEK | -45.33% |
| 2022 Q3 | 89.48 Million SEK | -4.21% |
| 2022 Q2 | 93.41 Million SEK | 7.96% |
| 2022 Q1 | 86.52 Million SEK | 27.52% |
| 2022 FY | 48.92 Million SEK | -27.9% |
| 2021 Q3 | 66.39 Million SEK | 13.09% |
| 2021 FY | 67.85 Million SEK | 30.48% |
| 2021 Q1 | 44.47 Million SEK | -14.48% |
| 2021 Q2 | 58.71 Million SEK | 32.02% |
| 2021 Q4 | 67.85 Million SEK | 2.19% |
| 2020 Q4 | 52 Million SEK | 85.36% |
| 2020 Q3 | 28.05 Million SEK | 52.17% |
| 2020 Q1 | 17.6 Million SEK | -9.77% |
| 2020 FY | 52 Million SEK | 166.53% |
| 2020 Q2 | 18.43 Million SEK | 4.73% |
| 2019 Q2 | 15.04 Million SEK | 12.35% |
| 2019 FY | 19.51 Million SEK | 20.71% |
| 2019 Q1 | 13.39 Million SEK | -17.15% |
| 2019 Q4 | 19.51 Million SEK | 13.4% |
| 2019 Q3 | 17.2 Million SEK | 14.35% |
| 2018 Q2 | 21.31 Million SEK | 208.36% |
| 2018 FY | 16.16 Million SEK | 146.44% |
| 2018 Q3 | 27.48 Million SEK | 28.97% |
| 2018 Q1 | 6.91 Million SEK | 5.38% |
| 2018 Q4 | 16.16 Million SEK | -41.2% |
| 2017 Q2 | 3.68 Million SEK | -38.98% |
| 2017 Q4 | 6.55 Million SEK | 69.35% |
| 2017 FY | 6.55 Million SEK | 8.36% |
| 2017 Q3 | 3.87 Million SEK | 5.04% |
| 2017 Q1 | 6.04 Million SEK | -0.18% |
| 2016 FY | 6.05 Million SEK | -17.03% |
| 2016 Q2 | 3.34 Million SEK | -26.71% |
| 2016 Q1 | 4.56 Million SEK | -37.38% |
| 2016 Q4 | 6.05 Million SEK | 33.65% |
| 2016 Q3 | 4.52 Million SEK | 35.27% |
| 2015 Q2 | 3.74 Million SEK | 0.0% |
| 2015 FY | 7.29 Million SEK | 28.61% |
| 2015 Q4 | 7.29 Million SEK | 0.0% |
| 2014 Q3 | 1.97 Million SEK | -50.38% |
| 2014 Q4 | 5.67 Million SEK | 187.34% |
| 2014 Q1 | 3.97 Million SEK | -63.74% |
| 2014 Q2 | 3.97 Million SEK | 0.0% |
| 2014 FY | 5.67 Million SEK | -48.3% |
| 2013 Q4 | 10.97 Million SEK | 2.53% |
| 2013 Q3 | 10.7 Million SEK | 0.0% |
| 2013 FY | 10.97 Million SEK | 90651.92% |
| 2013 Q1 | - SEK | -100.0% |
| 2012 Q4 | 12.08 Thousand SEK | 0.0% |
| 2012 FY | 12.08 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 61.669% |
| Ziccum AB (publ) | 6.38 Million SEK | -539.621% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -1632.047% |
| BioArctic AB (publ) | 139.5 Million SEK | 70.711% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -18.079% |
| Mendus AB (publ) | 51.22 Million SEK | 20.236% |
| Genovis AB (publ.) | 98.04 Million SEK | 58.327% |
| Intervacc AB (publ) | 21.68 Million SEK | -88.464% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -52.984% |
| Active Biotech AB (publ) | 13.4 Million SEK | -204.918% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 67.044% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -153.515% |
| Aptahem AB (publ) | 8.99 Million SEK | -354.099% |
| Kancera AB (publ) | 17.97 Million SEK | -127.272% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 11.522% |
| Fluicell AB (publ) | 8.91 Million SEK | -358.317% |
| Saniona AB (publ) | 86.08 Million SEK | 52.535% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -692.148% |
| Biovica International AB (publ) | 34.76 Million SEK | -17.522% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -250.18% |
| AcouSort AB (publ) | 10.37 Million SEK | -293.708% |
| Xintela AB (publ) | 14.01 Million SEK | -191.538% |
| Abliva AB (publ) | 16.78 Million SEK | -143.484% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 80.96% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -253.177% |
| OncoZenge AB (publ) | 1.69 Million SEK | -2304.885% |
| Amniotics AB (publ) | 10.54 Million SEK | -287.399% |
| 2cureX AB (publ) | 2.93 Million SEK | -1292.129% |
| CombiGene AB (publ) | 4.15 Million SEK | -883.133% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -823.159% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 97.39% |
| Camurus AB (publ) | 414.81 Million SEK | 90.15% |
| Corline Biomedical AB | 6.78 Million SEK | -501.841% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 33.408% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -113.207% |
| I-Tech AB | 16.2 Million SEK | -152.138% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 96.555% |
| Cyxone AB (publ) | 4.69 Million SEK | -770.452% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -206.565% |
| Biosergen AB | 5.08 Million SEK | -703.52% |
| Cantargia AB (publ) | 54.97 Million SEK | 25.67% |
| NextCell Pharma AB | 13.68 Million SEK | -198.479% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 43.133% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -196.691% |
| Nanologica AB (publ) | 79.32 Million SEK | 48.493% |
| SynAct Pharma AB | 51.83 Million SEK | 21.173% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -414.014% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -686.515% |
| LIDDS AB (publ) | 3.75 Million SEK | -987.833% |
| Lipum AB (publ) | 7.53 Million SEK | -442.04% |
| BioInvent International AB (publ) | 90.45 Million SEK | 54.828% |
| Alzinova AB (publ) | 9.33 Million SEK | -337.884% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 77.5% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -2177.536% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -120.931% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -964.591% |
| Simris Alg AB (publ) | 148.93 Million SEK | 72.566% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 42.548% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 91.526% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -220.614% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -462.796% |